egfr expression  (Agilent technologies)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Name:
    PD L1 IHC 22C3 pharmDx for use with Dako Omnis
    Description:
    PD L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti PD L1 Clone 22C3 intended for use in the detection of PD L1 protein in formalin fixed paraffin embedded FFPE non small cell lung cancer NSCLC tissue using EnVision FLEX visualization system for use on Dako Omnis PD L1 protein expression in NSCLC is determined by using Tumor Proportion Score TPS which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity The specimen should be considered to have PD L1 expression if TPS 1 PD L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA pembrolizumab See the KEYTRUDA product label for specific clinical circumstances guiding PD L1 testing PD L1 IHC 22C3 pharmDx on Dako Omnis The assay is a modular IHC assay for 60 tests The assay has been tailored especially with EnVision FLEX visualization system on the Dako Omnis instrument The complete assay consists of the following components to be ordered separately PD L1 IHC 22C3 pharmDx GE00621 5 for Dako Omnis Monoclonal Mouse Anti PD L1 Clone 22C3 RTU Dako Omnis with Negative Control Reagent EnVision FLEX High pH Dako Omnis GV80011 2 OR EnVision FLEX Mini Kit High pH Dako Omnis GV82311 2 EnVision FLEX Target Retrieval Solution Low pH 50x GV80511 2 EnVision FLEX Mouse Linker Dako Omnis GV82111 2 EnVision FLEX DAB Enhancer Dako Omnis GC80611 2 PD L1 Control Slides T139130 2 optional The assay requires Low pH Target Retrieval Mouse Linker and a DAB Enhancer but the PD L1 Control Slides are optional For countries outside of the United States see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy PD L1 IHC 22C3 pharmDx is subject to an exclusive trademark license to Dako Denmark A S KEYTRUDA is a registered trademark of Merck Sharp Dohme Corp a subsidiary of Merck Co Inc
    Catalog Number:
    PD-L1-IHC-22C3-PHARMDX,-FOR-USE-WITH-DAKO-OMNIS
    Price:
    None
    Category:
    Products Dako Omnis Solution For Ihc Ish Pharmdx Kit For Dako Omnis Pharmdx Kit Pd L1 Ihc 22C3 Pharmdx For Use With Dako Omnis
    Buy from Supplier


    Structured Review

    Agilent technologies egfr expression
    FISH analysis with two different <t>EGFR-specific</t> FISH probes. A , B , C , D : <t>Dako</t> Cytomation FISH probe mix (EGFR: red, CEN7: green), E , F , G , H : ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A , E : balanced disomy, B , F : balanced trisomy, C , G : low amplification, D , H : high amplification.
    PD L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti PD L1 Clone 22C3 intended for use in the detection of PD L1 protein in formalin fixed paraffin embedded FFPE non small cell lung cancer NSCLC tissue using EnVision FLEX visualization system for use on Dako Omnis PD L1 protein expression in NSCLC is determined by using Tumor Proportion Score TPS which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity The specimen should be considered to have PD L1 expression if TPS 1 PD L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA pembrolizumab See the KEYTRUDA product label for specific clinical circumstances guiding PD L1 testing PD L1 IHC 22C3 pharmDx on Dako Omnis The assay is a modular IHC assay for 60 tests The assay has been tailored especially with EnVision FLEX visualization system on the Dako Omnis instrument The complete assay consists of the following components to be ordered separately PD L1 IHC 22C3 pharmDx GE00621 5 for Dako Omnis Monoclonal Mouse Anti PD L1 Clone 22C3 RTU Dako Omnis with Negative Control Reagent EnVision FLEX High pH Dako Omnis GV80011 2 OR EnVision FLEX Mini Kit High pH Dako Omnis GV82311 2 EnVision FLEX Target Retrieval Solution Low pH 50x GV80511 2 EnVision FLEX Mouse Linker Dako Omnis GV82111 2 EnVision FLEX DAB Enhancer Dako Omnis GC80611 2 PD L1 Control Slides T139130 2 optional The assay requires Low pH Target Retrieval Mouse Linker and a DAB Enhancer but the PD L1 Control Slides are optional For countries outside of the United States see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy PD L1 IHC 22C3 pharmDx is subject to an exclusive trademark license to Dako Denmark A S KEYTRUDA is a registered trademark of Merck Sharp Dohme Corp a subsidiary of Merck Co Inc
    https://www.bioz.com/result/egfr expression/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr expression - by Bioz Stars, 2021-06
    86/100 stars

    Images

    1) Product Images from "Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC"

    Article Title: Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC

    Journal: Diagnostic Pathology

    doi: 10.1186/s13000-014-0165-0

    FISH analysis with two different EGFR-specific FISH probes. A , B , C , D : Dako Cytomation FISH probe mix (EGFR: red, CEN7: green), E , F , G , H : ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A , E : balanced disomy, B , F : balanced trisomy, C , G : low amplification, D , H : high amplification.
    Figure Legend Snippet: FISH analysis with two different EGFR-specific FISH probes. A , B , C , D : Dako Cytomation FISH probe mix (EGFR: red, CEN7: green), E , F , G , H : ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A , E : balanced disomy, B , F : balanced trisomy, C , G : low amplification, D , H : high amplification.

    Techniques Used: Fluorescence In Situ Hybridization, Amplification

    Immunohistochemical EGFR staining with four different antibodies showing differences in levels of EGFR expression in the same specimen of a squamous cell carcinoma (SSC) (original magnification × 400). (A) Staining intensity with Dako PharmDx 2+, (B) Staining intensity with 31G7 2+, (C) Staining intensity with 2.1E1 3+, (D) Staining intensity with SP84 1+.
    Figure Legend Snippet: Immunohistochemical EGFR staining with four different antibodies showing differences in levels of EGFR expression in the same specimen of a squamous cell carcinoma (SSC) (original magnification × 400). (A) Staining intensity with Dako PharmDx 2+, (B) Staining intensity with 31G7 2+, (C) Staining intensity with 2.1E1 3+, (D) Staining intensity with SP84 1+.

    Techniques Used: Immunohistochemistry, Staining, Expressing

    2) Product Images from "Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer"

    Article Title: Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    doi: 10.1186/1756-9966-29-125

    Immunocytochemical evaluation of EGFR on non small cell lung carcinoma . Immunohistochemistry for EGFR in large cell carcinoma (LCC) FNAC cell block evidencing a strong membrane immunoreactivity (score 3+). Original magnification ×400.
    Figure Legend Snippet: Immunocytochemical evaluation of EGFR on non small cell lung carcinoma . Immunohistochemistry for EGFR in large cell carcinoma (LCC) FNAC cell block evidencing a strong membrane immunoreactivity (score 3+). Original magnification ×400.

    Techniques Used: Immunohistochemistry, Blocking Assay

    3) Product Images from "Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer"

    Article Title: Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

    Journal: Gastric Cancer

    doi: 10.1007/s10120-014-0420-9

    Subset forest plots for progression-free survival ( a ) and overall survival ( b ). N-IRI nimotuzumab plus irinotecan, IRI irinotecan alone, EGFR epidermal growth factor receptor, IHC immunohistochemistry, ECOG Eastern Cooperative Oncology Group, PS performance status
    Figure Legend Snippet: Subset forest plots for progression-free survival ( a ) and overall survival ( b ). N-IRI nimotuzumab plus irinotecan, IRI irinotecan alone, EGFR epidermal growth factor receptor, IHC immunohistochemistry, ECOG Eastern Cooperative Oncology Group, PS performance status

    Techniques Used: Immunohistochemistry

    4) Product Images from "Detection of Circulating Tumor Cells in Human Peripheral Blood using Surface-Enhanced Raman Scattering Nanoparticles"

    Article Title: Detection of Circulating Tumor Cells in Human Peripheral Blood using Surface-Enhanced Raman Scattering Nanoparticles

    Journal: Cancer research

    doi: 10.1158/0008-5472.CAN-10-3069

    Detection of CTCs in patients’s blood samples and IHC staining for EGFR and cytokeratin
    Figure Legend Snippet: Detection of CTCs in patients’s blood samples and IHC staining for EGFR and cytokeratin

    Techniques Used: Immunohistochemistry, Staining

    5) Product Images from "Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer"

    Article Title: Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer

    Journal: Oncology Letters

    doi: 10.3892/ol.2016.5512

    Representative examples of positive and negative immunohistochemical staining for EGFR. Membrane staining was scored as follows: (A) 3+ for dark staining of the linear membrane visible at a magnification of ×100; (B) 2+ for intermediate staining
    Figure Legend Snippet: Representative examples of positive and negative immunohistochemical staining for EGFR. Membrane staining was scored as follows: (A) 3+ for dark staining of the linear membrane visible at a magnification of ×100; (B) 2+ for intermediate staining

    Techniques Used: Immunohistochemistry, Staining

    6) Product Images from "The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer"

    Article Title: The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms17071090

    Immunohistochemical analysis of EGFR (epidermal growth factor receptor) in PDAC (pancreatic duct adenocarcinoma)tissues. In PDAC tissues, immunoreactivity for EGFR was observed on the surface and in the cytoplasm of cancer cells ( A – C ), with no immunoreactivity in the surrounding stroma ( D ). The immunoreactivity was different in respective cases: ( A ) strong; ( B ) moderate; ( C ) weak expression; and ( D ) absent (scale bars, 200 μm).
    Figure Legend Snippet: Immunohistochemical analysis of EGFR (epidermal growth factor receptor) in PDAC (pancreatic duct adenocarcinoma)tissues. In PDAC tissues, immunoreactivity for EGFR was observed on the surface and in the cytoplasm of cancer cells ( A – C ), with no immunoreactivity in the surrounding stroma ( D ). The immunoreactivity was different in respective cases: ( A ) strong; ( B ) moderate; ( C ) weak expression; and ( D ) absent (scale bars, 200 μm).

    Techniques Used: Immunohistochemistry, Expressing

    7) Product Images from "A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases"

    Article Title: A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

    Journal: Oncotarget

    doi: 10.18632/oncotarget.8526

    EGFR-CAR NK-92 cells recognize and lyse EGFR positive cells of breast cancer cell lines ( A ) Expression of EGFR scFv on EGFR-CAR-transduced NK-92 cells, determined by flow cytometry using a goat anti-mouse F(ab′) 2 polyclonal antibody. ( B ) IFN-γ release by empty vector (EV)-transduced or EGFR-CAR-transduced NK-92 cells in the absence or presence of MDA-MB-231, MDA-MB-468 or MCF-7 cells using a standard ELISA assay. ** P
    Figure Legend Snippet: EGFR-CAR NK-92 cells recognize and lyse EGFR positive cells of breast cancer cell lines ( A ) Expression of EGFR scFv on EGFR-CAR-transduced NK-92 cells, determined by flow cytometry using a goat anti-mouse F(ab′) 2 polyclonal antibody. ( B ) IFN-γ release by empty vector (EV)-transduced or EGFR-CAR-transduced NK-92 cells in the absence or presence of MDA-MB-231, MDA-MB-468 or MCF-7 cells using a standard ELISA assay. ** P

    Techniques Used: Expressing, Flow Cytometry, Cytometry, Plasmid Preparation, Multiple Displacement Amplification, Enzyme-linked Immunosorbent Assay

    Expression of EGFR in breast cancer cell lines and tissues ( A ) Expression of EGFR on the cell surface of breast cancer cell lines (MDA-MB-231, MDA-MB-468, and MCF-7) detected by flow cytometry. ( B ) Hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) of EGFR expression for tumor tissues from patients with primary breast cancer and brain metastases.
    Figure Legend Snippet: Expression of EGFR in breast cancer cell lines and tissues ( A ) Expression of EGFR on the cell surface of breast cancer cell lines (MDA-MB-231, MDA-MB-468, and MCF-7) detected by flow cytometry. ( B ) Hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) of EGFR expression for tumor tissues from patients with primary breast cancer and brain metastases.

    Techniques Used: Expressing, Multiple Displacement Amplification, Flow Cytometry, Cytometry, Staining, Immunohistochemistry

    Related Articles

    Fluorescence In Situ Hybridization:

    Article Title: PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Article Snippet: .. Additionally, the sample needed to have > 100 tumor cells for the PD‐L1 test and > 50 tumors cells for ALK and ROS1 FISH tests., In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes., PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). .. Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

    Immunohistochemistry:

    Article Title: PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Article Snippet: .. Additionally, the sample needed to have > 100 tumor cells for the PD‐L1 test and > 50 tumors cells for ALK and ROS1 FISH tests., In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes., PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). .. Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

    Article Title: Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
    Article Snippet: .. We compared the effectiveness of PD-L1 expression examination of two IHC assays with 22C3 (Dako) and SP142 antibodies (Ventana). .. IHC tests were performed in resected tissue samples and in cellblocks from bronchoscopy biopsies (formalin-fixed paraffin-embedded).

    Article Title: Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
    Article Snippet: .. SQCC of the right middle lobe showed 100% tumor proportion score (TPS) for PD-L1 (Agilent Dako IHC 22C3 platform) ( B) and no expression of EGFR mutations (Roche cobas® EGFR Mutation Test v2) and anaplastic lymphoma kinase (ALK) rearrangements (Histofine ALK iAEP® Kit). .. Adenocarcinoma of the right lower lobe showed exon 19 deletion and no expression of PD-L1.

    Article Title: Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
    Article Snippet: .. The 22C3 test (PD-L1 IHC 22C3 pharmDx, Agilent Technologies, Inc., Santa Clara, CA, USA) is currently the only test used as a companion diagnostic test (CDX) for the administration of pembrolizumab as first line treatement in advanced or metastatic NSCLC [ ]. ..

    Article Title: PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
    Article Snippet: The analysis was performed on a Dako Omnis IHC platform (GI100, Santa Clara, CA, USA). .. Selected reagents were used in the IHC analysis: PD-L1 IHC 22C3 pharmDx staining set (GE006) including monoclonal PD-L1 antibody 22C3 clone (Dako Omnis, Santa Clara, CA, USA), negative control (Dako Omnis, Santa Clara, CA, USA), high pH detective sys- tem EnVision Flex Mini Kit (Dako Omnis, Santa Clara, CA, USA, GV823), wash buffer (20x) (GC807, Dako Omnis, Santa Clara, CA, USA). .. In order to remove the paraffin, a low pH Envision Flex Target Retrieval Solution (Dako Omnis, Santa Clara, CA, USA) was used.

    Article Title: Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
    Article Snippet: In the competence test set, the consensus scores for PD-L1 TC expression for samples stained using the VENTANA PD-L1 (SP263) assay were: 3 cases < 1%; 3 cases ≥1– < 25%; 3 cases ≥25– < 50%; 9 cases ≥50%. .. For samples stained using the Dako PD-L1 IHC PharmDx 22C3 assay, expression was classified as follows: 2 cases < 1%; 6 cases ≥1– < 25%; 4 cases ≥25– < 50%; 6 cases ≥50%. ..

    Staining:

    Article Title: PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Article Snippet: .. Additionally, the sample needed to have > 100 tumor cells for the PD‐L1 test and > 50 tumors cells for ALK and ROS1 FISH tests., In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes., PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). .. Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

    Article Title: PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
    Article Snippet: The analysis was performed on a Dako Omnis IHC platform (GI100, Santa Clara, CA, USA). .. Selected reagents were used in the IHC analysis: PD-L1 IHC 22C3 pharmDx staining set (GE006) including monoclonal PD-L1 antibody 22C3 clone (Dako Omnis, Santa Clara, CA, USA), negative control (Dako Omnis, Santa Clara, CA, USA), high pH detective sys- tem EnVision Flex Mini Kit (Dako Omnis, Santa Clara, CA, USA, GV823), wash buffer (20x) (GC807, Dako Omnis, Santa Clara, CA, USA). .. In order to remove the paraffin, a low pH Envision Flex Target Retrieval Solution (Dako Omnis, Santa Clara, CA, USA) was used.

    Article Title: Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
    Article Snippet: In the competence test set, the consensus scores for PD-L1 TC expression for samples stained using the VENTANA PD-L1 (SP263) assay were: 3 cases < 1%; 3 cases ≥1– < 25%; 3 cases ≥25– < 50%; 9 cases ≥50%. .. For samples stained using the Dako PD-L1 IHC PharmDx 22C3 assay, expression was classified as follows: 2 cases < 1%; 6 cases ≥1– < 25%; 4 cases ≥25– < 50%; 6 cases ≥50%. ..

    Formalin-fixed Paraffin-Embedded:

    Article Title: PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Article Snippet: .. Additionally, the sample needed to have > 100 tumor cells for the PD‐L1 test and > 50 tumors cells for ALK and ROS1 FISH tests., In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes., PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). .. Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

    Expressing:

    Article Title: Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
    Article Snippet: .. We compared the effectiveness of PD-L1 expression examination of two IHC assays with 22C3 (Dako) and SP142 antibodies (Ventana). .. IHC tests were performed in resected tissue samples and in cellblocks from bronchoscopy biopsies (formalin-fixed paraffin-embedded).

    Article Title: Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
    Article Snippet: .. SQCC of the right middle lobe showed 100% tumor proportion score (TPS) for PD-L1 (Agilent Dako IHC 22C3 platform) ( B) and no expression of EGFR mutations (Roche cobas® EGFR Mutation Test v2) and anaplastic lymphoma kinase (ALK) rearrangements (Histofine ALK iAEP® Kit). .. Adenocarcinoma of the right lower lobe showed exon 19 deletion and no expression of PD-L1.

    Article Title: Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
    Article Snippet: In the competence test set, the consensus scores for PD-L1 TC expression for samples stained using the VENTANA PD-L1 (SP263) assay were: 3 cases < 1%; 3 cases ≥1– < 25%; 3 cases ≥25– < 50%; 9 cases ≥50%. .. For samples stained using the Dako PD-L1 IHC PharmDx 22C3 assay, expression was classified as follows: 2 cases < 1%; 6 cases ≥1– < 25%; 4 cases ≥25– < 50%; 6 cases ≥50%. ..

    Mutagenesis:

    Article Title: Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
    Article Snippet: .. SQCC of the right middle lobe showed 100% tumor proportion score (TPS) for PD-L1 (Agilent Dako IHC 22C3 platform) ( B) and no expression of EGFR mutations (Roche cobas® EGFR Mutation Test v2) and anaplastic lymphoma kinase (ALK) rearrangements (Histofine ALK iAEP® Kit). .. Adenocarcinoma of the right lower lobe showed exon 19 deletion and no expression of PD-L1.

    Diagnostic Assay:

    Article Title: Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
    Article Snippet: .. The 22C3 test (PD-L1 IHC 22C3 pharmDx, Agilent Technologies, Inc., Santa Clara, CA, USA) is currently the only test used as a companion diagnostic test (CDX) for the administration of pembrolizumab as first line treatement in advanced or metastatic NSCLC [ ]. ..

    Article Title: Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
    Article Snippet: In patients with metastatic NSCLC and no prior systemic therapy, pembrolizumab was recently approved in the United States for the treatment of patients with PD-L1 expression ≥50% based on the results of the KEYNOTE-024 (NCT02142738) study [ ]. .. Based on these data, pembrolizumab was approved in conjunction with a companion diagnostic test, the PD-L1 IHC 22C3 pharmDx assay (Dako, Carpinteria, CA) for use on the Dako Autostainer Link 48 (ASL48) platform [ , ]. .. However, pathology laboratories without the ASL48 platform are currently unable to provide PD-L1 immunohistochemistry (IHC) staining to identify patients with NSCLC suitable for treatment with pembrolizumab.

    Negative Control:

    Article Title: PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
    Article Snippet: The analysis was performed on a Dako Omnis IHC platform (GI100, Santa Clara, CA, USA). .. Selected reagents were used in the IHC analysis: PD-L1 IHC 22C3 pharmDx staining set (GE006) including monoclonal PD-L1 antibody 22C3 clone (Dako Omnis, Santa Clara, CA, USA), negative control (Dako Omnis, Santa Clara, CA, USA), high pH detective sys- tem EnVision Flex Mini Kit (Dako Omnis, Santa Clara, CA, USA, GV823), wash buffer (20x) (GC807, Dako Omnis, Santa Clara, CA, USA). .. In order to remove the paraffin, a low pH Envision Flex Target Retrieval Solution (Dako Omnis, Santa Clara, CA, USA) was used.

    Transmission Electron Microscopy:

    Article Title: PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
    Article Snippet: The analysis was performed on a Dako Omnis IHC platform (GI100, Santa Clara, CA, USA). .. Selected reagents were used in the IHC analysis: PD-L1 IHC 22C3 pharmDx staining set (GE006) including monoclonal PD-L1 antibody 22C3 clone (Dako Omnis, Santa Clara, CA, USA), negative control (Dako Omnis, Santa Clara, CA, USA), high pH detective sys- tem EnVision Flex Mini Kit (Dako Omnis, Santa Clara, CA, USA, GV823), wash buffer (20x) (GC807, Dako Omnis, Santa Clara, CA, USA). .. In order to remove the paraffin, a low pH Envision Flex Target Retrieval Solution (Dako Omnis, Santa Clara, CA, USA) was used.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Agilent technologies human epidermal growth factor receptor egfr
    High <t>EGFR</t> expression is a strongly associated with high ND. (A) Microscopic analysis of cell membrane EGFR <t>immunohistochemical</t> staining. EGFR expression was graded using a 3-point scale, where 1+ = light staining of more than 10% of the specimens, 2+ = moderate staining of more than 10% and less than or equal to 30% of the specimens, and 3+ = strong staining of more than 30% of the specimens. (B) Statistical analysis of EGFR expression using Student's t -test. EGFR 2+/3+ expression group included more patients with high ND than the EGFR 1+ group. The most suitable ND cutoff level was deemed ND of 35%. (c) Kaplan–Meier curves indicate that EGFR 2+/3+ expression was significantly associated with poor outcome in patients with 13th JGCA stage II/III disease ( P = 0.039). (D) ND ≥35 was significantly associated with poor outcome ( P = 0.0012).
    Human Epidermal Growth Factor Receptor Egfr, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human epidermal growth factor receptor egfr/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human epidermal growth factor receptor egfr - by Bioz Stars, 2021-06
    86/100 stars
      Buy from Supplier

    86
    Agilent technologies egfr expression
    FISH analysis with two different <t>EGFR-specific</t> FISH probes. A , B , C , D : <t>Dako</t> Cytomation FISH probe mix (EGFR: red, CEN7: green), E , F , G , H : ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A , E : balanced disomy, B , F : balanced trisomy, C , G : low amplification, D , H : high amplification.
    Egfr Expression, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr expression/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr expression - by Bioz Stars, 2021-06
    86/100 stars
      Buy from Supplier

    86
    Agilent technologies mouse anti human egfr monoclonal antibody
    <t>EGFR</t> (epidermal growth factor receptor) gene status in adrenocortical neoplasms: (a) This image demonstrates strong membrane EGFR expression (3+) in adrenocortical carcinoma, as detected by <t>immunohistochemistry.</t> (b) This image demonstrates an absence of membrane EGFR expression in adrenocortical adenoma, as detected by immunohistochemistry. (c) The cancer cells demonstrate high polysomy on chromosome 7 in adrenocortical carcinoma, as detected by FISH(fluorescence in situ hybridization). (d) The tumor cells display disomy for the EGFR in adrenocortical adenoma, as detected by FISH (Green signals represent the chromosome 7 centromere, and red signals represent the EGFR gene).
    Mouse Anti Human Egfr Monoclonal Antibody, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human egfr monoclonal antibody/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti human egfr monoclonal antibody - by Bioz Stars, 2021-06
    86/100 stars
      Buy from Supplier

    86
    Agilent technologies egfr staining
    Biomarker expression in tumor-positive lymph nodes Biomarker expression in tumor-positive lymph nodes for the different biomarkers <t>αvβ6</t> (A) , CEACAM5 (B) , <t>EGFR</t> (C) , uPAR (D) , CathE (E) (Objective 1x, insert 20x).
    Egfr Staining, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr staining/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr staining - by Bioz Stars, 2021-06
    86/100 stars
      Buy from Supplier

    Image Search Results


    High EGFR expression is a strongly associated with high ND. (A) Microscopic analysis of cell membrane EGFR immunohistochemical staining. EGFR expression was graded using a 3-point scale, where 1+ = light staining of more than 10% of the specimens, 2+ = moderate staining of more than 10% and less than or equal to 30% of the specimens, and 3+ = strong staining of more than 30% of the specimens. (B) Statistical analysis of EGFR expression using Student's t -test. EGFR 2+/3+ expression group included more patients with high ND than the EGFR 1+ group. The most suitable ND cutoff level was deemed ND of 35%. (c) Kaplan–Meier curves indicate that EGFR 2+/3+ expression was significantly associated with poor outcome in patients with 13th JGCA stage II/III disease ( P = 0.039). (D) ND ≥35 was significantly associated with poor outcome ( P = 0.0012).

    Journal: Cancer Medicine

    Article Title: Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer

    doi: 10.1002/cam4.311

    Figure Lengend Snippet: High EGFR expression is a strongly associated with high ND. (A) Microscopic analysis of cell membrane EGFR immunohistochemical staining. EGFR expression was graded using a 3-point scale, where 1+ = light staining of more than 10% of the specimens, 2+ = moderate staining of more than 10% and less than or equal to 30% of the specimens, and 3+ = strong staining of more than 30% of the specimens. (B) Statistical analysis of EGFR expression using Student's t -test. EGFR 2+/3+ expression group included more patients with high ND than the EGFR 1+ group. The most suitable ND cutoff level was deemed ND of 35%. (c) Kaplan–Meier curves indicate that EGFR 2+/3+ expression was significantly associated with poor outcome in patients with 13th JGCA stage II/III disease ( P = 0.039). (D) ND ≥35 was significantly associated with poor outcome ( P = 0.0012).

    Article Snippet: Immunohistochemical staining of the EGFR The primary antibodies used for immunohistochemical (IHC) assays were the mouse monoclonal antibodies against the human epidermal growth factor receptor (EGFR) that are included in the EGFR pharmDx kit (Dako-Japan, Tokyo, Japan).

    Techniques: Expressing, Immunohistochemistry, Staining

    FISH analysis with two different EGFR-specific FISH probes. A , B , C , D : Dako Cytomation FISH probe mix (EGFR: red, CEN7: green), E , F , G , H : ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A , E : balanced disomy, B , F : balanced trisomy, C , G : low amplification, D , H : high amplification.

    Journal: Diagnostic Pathology

    Article Title: Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC

    doi: 10.1186/s13000-014-0165-0

    Figure Lengend Snippet: FISH analysis with two different EGFR-specific FISH probes. A , B , C , D : Dako Cytomation FISH probe mix (EGFR: red, CEN7: green), E , F , G , H : ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A , E : balanced disomy, B , F : balanced trisomy, C , G : low amplification, D , H : high amplification.

    Article Snippet: Scoring with method (B) showed a similar EGFR expression in SCC and ADC for Dako PharmDx and 31G7.

    Techniques: Fluorescence In Situ Hybridization, Amplification

    Immunohistochemical EGFR staining with four different antibodies showing differences in levels of EGFR expression in the same specimen of a squamous cell carcinoma (SSC) (original magnification × 400). (A) Staining intensity with Dako PharmDx 2+, (B) Staining intensity with 31G7 2+, (C) Staining intensity with 2.1E1 3+, (D) Staining intensity with SP84 1+.

    Journal: Diagnostic Pathology

    Article Title: Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC

    doi: 10.1186/s13000-014-0165-0

    Figure Lengend Snippet: Immunohistochemical EGFR staining with four different antibodies showing differences in levels of EGFR expression in the same specimen of a squamous cell carcinoma (SSC) (original magnification × 400). (A) Staining intensity with Dako PharmDx 2+, (B) Staining intensity with 31G7 2+, (C) Staining intensity with 2.1E1 3+, (D) Staining intensity with SP84 1+.

    Article Snippet: Scoring with method (B) showed a similar EGFR expression in SCC and ADC for Dako PharmDx and 31G7.

    Techniques: Immunohistochemistry, Staining, Expressing

    EGFR (epidermal growth factor receptor) gene status in adrenocortical neoplasms: (a) This image demonstrates strong membrane EGFR expression (3+) in adrenocortical carcinoma, as detected by immunohistochemistry. (b) This image demonstrates an absence of membrane EGFR expression in adrenocortical adenoma, as detected by immunohistochemistry. (c) The cancer cells demonstrate high polysomy on chromosome 7 in adrenocortical carcinoma, as detected by FISH(fluorescence in situ hybridization). (d) The tumor cells display disomy for the EGFR in adrenocortical adenoma, as detected by FISH (Green signals represent the chromosome 7 centromere, and red signals represent the EGFR gene).

    Journal: Diagnostic Pathology

    Article Title: Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status

    doi: 10.1186/1746-1596-9-19

    Figure Lengend Snippet: EGFR (epidermal growth factor receptor) gene status in adrenocortical neoplasms: (a) This image demonstrates strong membrane EGFR expression (3+) in adrenocortical carcinoma, as detected by immunohistochemistry. (b) This image demonstrates an absence of membrane EGFR expression in adrenocortical adenoma, as detected by immunohistochemistry. (c) The cancer cells demonstrate high polysomy on chromosome 7 in adrenocortical carcinoma, as detected by FISH(fluorescence in situ hybridization). (d) The tumor cells display disomy for the EGFR in adrenocortical adenoma, as detected by FISH (Green signals represent the chromosome 7 centromere, and red signals represent the EGFR gene).

    Article Snippet: Immunohistochemical study EGFR protein expression was evaluated by immunohistochemistry using a mouse anti-human EGFR monoclonal antibody (clone 2-18C9, Pharm Dx kit, Dako North America, Inc., Via Real, Carpinteria, CA, USA), according to the manufacturer’s instructions.

    Techniques: Expressing, Immunohistochemistry, Fluorescence In Situ Hybridization, In Situ Hybridization

    Biomarker expression in tumor-positive lymph nodes Biomarker expression in tumor-positive lymph nodes for the different biomarkers αvβ6 (A) , CEACAM5 (B) , EGFR (C) , uPAR (D) , CathE (E) (Objective 1x, insert 20x).

    Journal: Oncotarget

    Article Title: Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma

    doi: 10.18632/oncotarget.18232

    Figure Lengend Snippet: Biomarker expression in tumor-positive lymph nodes Biomarker expression in tumor-positive lymph nodes for the different biomarkers αvβ6 (A) , CEACAM5 (B) , EGFR (C) , uPAR (D) , CathE (E) (Objective 1x, insert 20x).

    Article Snippet: For αvβ6 and EGFR staining, antigen retrieval was performed with 0.4% pepsin incubation (Dako) at 37°C for 10 min.

    Techniques: Biomarker Assay, Expressing

    Expression patterns of investigated markers Representative images of immunohistochemically staining patterns in PDAC of all molecular markers; αvβ6 (A-C) , CEACAM5 (D-F) , EGFR (G-I) , Thy1 (J-L) , uPAR (M-O) , CathE (P-R) , cMET (S-U) showing respectively from left to right normal pancreatic tissue, CP, PDAC and graphical representation of mean percentage staining on all the tissue slides (*: p

    Journal: Oncotarget

    Article Title: Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma

    doi: 10.18632/oncotarget.18232

    Figure Lengend Snippet: Expression patterns of investigated markers Representative images of immunohistochemically staining patterns in PDAC of all molecular markers; αvβ6 (A-C) , CEACAM5 (D-F) , EGFR (G-I) , Thy1 (J-L) , uPAR (M-O) , CathE (P-R) , cMET (S-U) showing respectively from left to right normal pancreatic tissue, CP, PDAC and graphical representation of mean percentage staining on all the tissue slides (*: p

    Article Snippet: For αvβ6 and EGFR staining, antigen retrieval was performed with 0.4% pepsin incubation (Dako) at 37°C for 10 min.

    Techniques: Expressing, Staining